The optimization of tumor-to-kidney ratios would considerably enhance the viability and applicability of our CXCR4-targeting radiopharmaceutical, considering that both [68Ga]Ga-BL02 and [18F]BL08 showed comparable, if not superior, PET imaging capabilities as compared to other CXCR4-targeting radiotracers [24,28,46]. The gene discussed is CXCR4; the disease is neoplasm.